EGFR and non-small cell lung carcinoma: In addition, around 20–30% of NSCLC with an activating mutation display an intrinsic resistance to EGFR-TKI, the fast mutational characteristics leading to 50% resistance to first- and second-generation EGFR-TKIs within 9 to 14 months.